0 Items
Select Page

Arenavirus Receptors

The Native Antigen Company manufacturers highly purified virus-host cell receptors using state-of-the-art expression and purification techniques. On request we can also undertake custom preparation of recombinant and native proteins for a broad range of disease states.

Arenavirus Receptors Background

The Arenaviridae are a family of viruses whose members are generally associated with rodent-transmitted diseases in humans. The family is divided into three genera based on their natural hosts; Mammarenaviridae, (mammals), Reptarenaviridae (reptiles), and Hartmaniviridae (fish). Mammarenaviridae are further classified into the regions of their origins, including the Old World (OW) viruses found in West Africa and the New World (NW) viruses found in South America.

Arenaviruses are negative-sense, single-stranded RNA viruses belonging to the family Arenaviridae. The virus particles (average diameter 110-130 nm) are enveloped, ambisense single-stranded RNA viruses with a membrane envelope containing the surface glycoprotein (GP) subunits surrounding a capsid, which consists of the Z matrix protein. Inside the capsid are the L RNA-dependent RNA polymerase and the viral bi-segmented genome encapsulated by the nucleoprotein (NP). Cell entry is mediated by GP, which is first expressed as the glycoprotein precursor complex (GPC). A host protease cleaves GPC into its three final subunits: GP1, GP2, and SSP (Stable Signal Peptide), which form heterotrimers on the cell membrane surface. GP1 forms spikes protruding from the viral envelope and is responsible for interacting with entry receptors, while GP2 is a class 1 fusion transmembrane protein with a 6-helix domain.

Many arenaviruses are zoonotic pathogens and are generally associated with rodent-transmitted disease in humans. Each virus usually is associated with a particular rodent host species in which it is maintained. Human infection with an arenavirus is incidental to the natural cycle of the viruses and occurs when an individual comes into contact with the excretions or materials contaminated with the excretions of an infected rodent. The virus enters by inhalation of air-borne viral particles or by eating and/or drinking virus contaminated food or water, respectively. These diseases pose a significant threat to public health, both in the regions where they are occurring and non-endemic areas they are imported into by infected travellers. For example, when the Old World Lassa virus turns into Lassa fever, this usually results in significant mortality. Similarly, the New World Junin virus causes Argentine hemorrhagic fever with a case fatality of 15-30%. There is increasing concern about the potential for arenaviruses to spread across regions and initiate worldwide pandemics.

There are currently very few treatment methods available and the only clinically successful anti-arenaviral vaccine is the Argentinian anti-JUNV Candid #1 strain. The majority of arenaviral drug discovery has focused on small molecule inhibitors of the mammarenaviral glycoprotein and cell entry, using amphipathic DNA polymers to block the interaction between LCMV GP and α-dystroglycan. Clotrimazole derivatives have also been shown to inhibit arenaviral membrane fusion. However, much more research is required for the future development of effective vaccine and therapeutic interventions against mammarenaviruses.

References

  1. Brisse and Hinh (2019). Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. Front Immunol. 10: 372.
  2. Arenaviridae (2013). Centers for Disease Control and Prevention.

 

 

Arenavirus Receptors

We offer a range of arenavirus receptors comprising highly purified recombinant proteins known to bind to a broad spectrum of viruses.

 

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 7 =

Live Customer Feedback